The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Abstract
Hepatocellular carcinoma is often diagnosed at an advanced stage, when it is not amenable to curative therapies. There is no effective chemotherapy. Advances in cancer biology suggest that a limited number of pathways are responsible for initiating and maintaining dysregulated cell proliferation, which is the major cellular alteration responsible for the cancer phenotype. New treatments in development target several of these critical pathways, including agents targeting the receptor tyrosine kinase pathways, the Wnt/beta-catenin signaling pathway, the ubiquitin/proteasome degradation pathway, the epigenetic DNA methylation and histone deacetylation pathways, the PI3 kinase/AKT/mTOR pathway, angiogenic pathways, and telomerase. Several of these approaches hold significant promise for improving the long-term outcome of patients with advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, these approaches must be coupled with new strategies for halting or reversing the progression of chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 1×
“receptor (EGFR) tyrosine kinase inhibitor gefitinib (Iressa) on the subgroup of non–small cell lung cancers with particular activating somatic mutations in the EGFR coding region.(20,21) Cure of a case of advanced liver cancer after treatment with imatinib has been reported.”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Caught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Green, D. R., & Evan, G. I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00024-7 · Cited by 1,254
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Hepatocellular carcinoma: Recent trends in the United States
El-Serag, H. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.013 · Cited by 972
Self-renewal and solid tumor stem cells
Al-Hajj, M., & Clarke, M. F. (2004) · Oncogene · doi:10.1038/sj.onc.1207947 · Cited by 914
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
Axis of evil: molecular mechanisms of cancer metastasis
Bogenrieder, T., & Herlyn, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206757 · Cited by 593
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 570
Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase
Zhang, Y., Chang, C., Gehling, D. J., Hemmati-Brivanlou, A., & Derynck, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.974 · Cited by 524
Dissecting p53 tumor suppressor functions in vivo
Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00047-8 · Cited by 485
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., & Torbenson, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0941 · Cited by 382
Histone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Colnot, S., Decaens, T., Niwa-Kawakita, M., Godard, C., Hamard, G., Kahn, A., Giovannini, M., & Perret, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404761101 · Cited by 328
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
Chan, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602162 · Cited by 301
Dong, Y., Hakimi, M.-A., Chen, X., Kumaraswamy, E., Cooch, N. S., Godwin, A. K., & Shiekhattar, R. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00424-6 · Cited by 276
Han, J. W., Ahn, S. H., Park, S. H., Wang, S. Y., Bae, G., Seo, D. W., Kwon, H. K., Hong, S., Lee, H. Y., Lee, Y., et al. (2000) · PubMed · Cited by 273
Oncogenic protein tyrosine kinases: Kit as a human oncogenic tyrosine kinase
Kitamura, Y., & Hirotab, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4273-y · Cited by 260
You, L., He, B., Xu, Z., Uematsu, K., Mazieres, J., Mikami, I., Reguart, N., Moody, T. W., Kitajewski, J., McCormick, F., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207844 · Cited by 258
Gratton, J.-P., Lin, M. I., Yu, J., Weiss, E. D., Jiang, Z. L., Fairchild, T. A., Iwakiri, Y., Groszmann, R., Claffey, K. P., Cheng, Y.-C., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00168-5 · Cited by 238
Zhu, W.-G., & Otterson, G. (2003) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011033482440 · Cited by 226
The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications
Burger, A. M., & Seth, A. K. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.006 · Cited by 224
Kwon, S. H., Ahn, S. H., Kim, Y. K., Bae, G.-U., Yoon, J. W., Hong, S., Lee, H. Y., Lee, Y.-W., Lee, H.-W., & Han, J.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106699200 · Cited by 215
Wnt/?-catenin-pathway as a molecular target for future anti-cancer therapeutics
Dihlmann, S., & von Knebel Doeberitz, M. (2005) · International Journal of Cancer · doi:10.1002/ijc.20609 · Cited by 201
You, L., He, B., Xu, Z., Uematsu, K., Mazieres, J., Fujii, N., Mikami, I., Reguart, N., McIntosh, J. K., Kashani-Sabet, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1227 · Cited by 194
Boon, E. M. J., Keller, J. J., Wormhoudt, T. A. M., Giardiello, F. M., Offerhaus, G. J. A., van der Neut, R., & Pals, S. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601505 · Cited by 190
Kim, K., Bae, S. K., Lee, O., Bae, M.-H., Lee, M. J., & Park, B. C. (1998) · PubMed · Cited by 190
Regulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179
Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis
Miura, N., Horikawa, I., Nishimoto, A., Ohmura, H., Ito, H., Hirohashi, S., Shay, J. W., & Oshimura, M. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00329-9 · Cited by 174 · cited 14×
“Activation of the Wnt pathway occurs in 30 to 40% of HCCs and is due to mutations in the b-catenin gene in 12 to 26% of human HCCs and to mutations in AXIN1 or AXIN2 in 8 to 13% of human HCCs.31 Inactivation of APC in mouse liver has been shown to lead to the development of HCCs.32 Wnts are involved in regulation of l…”
BackgroundInfluentialHöpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., & Scherübl, H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.024 · Cited by 173
Telomerase and human tumorigenesis
Stewart, S. A., & Weinberg, R. A. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0339 · Cited by 169
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics
Seimiya, H., Muramatsu, Y., Ohishi, T., & Tsuruo, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.021 · Cited by 166
Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease
Kojima, H., Yokosuka, O., Imazeki, F., Saisho, H., & Omata, M. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024303 · Cited by 162
Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent
Adjei, A. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040010 · Cited by 162
Telomeres, telomerase, and myc. An update
Cerni, C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(99)00091-5 · Cited by 160
Jones, A. V., & Cross, N. C. P. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4272-z · Cited by 157
Yamashita, Y., Shimada, M., Harimoto, N., Rikimaru, T., Shirabe, K., Tanaka, S., & Sugimachi, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10699 · Cited by 156
Endostatin is a potential inhibitor of Wnt signaling
Hanai, J., Gloy, J., Karumanchi, S. A., Kale, S., Tang, J., Hu, G., Chan, B., Ramchandran, R., Jha, V., Sukhatme, V. P., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203064 · Cited by 156
Herold, C., Ganslmayer, M., Ocker, M., Hermann, M., Geerts, A. E., Hahn, E. G., & Schuppan, D. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00257-4 · Cited by 143
Suksaweang, S., Lin, C., Jiang, T., Hughes, M. W., Widelitz, R. B., & Chuong, C. (2003) · Developmental Biology · doi:10.1016/j.ydbio.2003.10.010 · Cited by 138
Parkin gene alterations in hepatocellular carcinoma
Wang, F., Denison, S. R., Lai, J., Philips, L. A., Montoya, D., Kock, N., Schüle, B., Klein, C., Shridhar, V., Roberts, L. R., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20020 · Cited by 130
Self-citationWilliams, J. L., Nath, N., Chen, J., Hundley, T. R., Gao, J., Kopelovich, L., Kashfi, K., & Rigas, B. (2003) · PubMed · Cited by 116
The Absence of p53 Promotes Metastasis in a Novel Somatic Mouse Model for Hepatocellular Carcinoma
Lewis, B. C., Klimstra, D. S., Socci, N. D., Xu, S., Koutcher, J. A., & VARMUS, H. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1228-1237.2005 · Cited by 112
Dihlmann, S., Klein, S., & Mv, M. V. K. D. (2003) · PubMed · Cited by 108
Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity
Zhou, L., An, N., Haydon, R. C., Zhou, Q., Cheng, H., Peng, Y., Jiang, W., Luu, H. H., Vanichakarn, P., Szatkowski, J. P., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00013-2 · Cited by 104
Hawcroft, G., D'Amico, M., Albanese, C., Markham, A. F., Pestell, R., & Hull, M. A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.107 · Cited by 100
Histone Deacetylase Inhibitors and Anticancer Therapy
Kouraklis, G. P., & Theocharis, S. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023353921 · Cited by 99
Thalidomide in the treatment of patients with hepatocellular carcinoma: A Phase II trial
Patt, Y. Z., Hassan, M. M., Lozano, R. D., Nooka, A. K., Schnirer, I. I., Zeldis, J. B., Abbruzzese, J. L., & Brown, T. D. (2005) · Cancer · doi:10.1002/cncr.20821 · Cited by 96
Adjei, A. A., Dy, G. K., Erlichman, C., Reid, J. M., Sloan, J. A., Pitot, H. C., Alberts, S. R., Goldberg, R. M., Hanson, L. J., Atherton, P. J., et al. (2003) · PubMed · Cited by 88
Cheong, J., Chong, S. Y., Kim, J. Y., Eom, J.-I., Jeung, H. K., Maeng, H. M., Lee, S., & Min, Y. H. (2003) · PubMed · Cited by 85
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Lee, J., Park, J. O., Kim, W. S., Park, S. H., Park, K. W., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0837-7 · Cited by 83
Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo
Yamamoto, H., Fujimoto, J., Okamoto, E., Furuyama, J.-I., Tamaoki, T., & Hashimoto-Tamaoki, T. (1998) · International Journal of Cancer · Cited by 71
Durable Clinical Response of Refractory Hepatocellular Carcinoma to Orally Administered Thalidomide
Patt, Y. Z., Hassan, M. M., Lozano, R. D., Ellis, L. M., Peterson, J. A., & Waugh, K. A. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200006000-00023 · Cited by 70
Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma
Nagao, K., Tomimatsu, M., Endo, H., Hisatomi, H., & Hikiji, K. (1999) · Journal of Gastroenterology · doi:10.1007/s005350050220 · Cited by 63
Relevance network between chemosensitivity and transcriptome in human hepatoma cells.
Moriyama, M., Hoshida, Y., Otsuka, M., Nishimura, S., Kato, N., Goto, T., Taniguchi, H., Shiratori, Y., Seki, N., & Omata, M. (2003) · PubMed · Cited by 59
Kurokawa, Y., Matoba, R., Nagano, H., Sakon, M., Takemasa, I., Nakamori, S., Dono, K., Umeshita, K., Ueno, N., Ishii, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0243 · Cited by 53
Lee, T. K., Man, K., Ho, J. W., Wang, X. H., Poon, R. T. P., Sun, C. K.-W., Ng, K. T., Ng, I. O., Xu, R., & Fan, S. T. (2004) · Carcinogenesis · doi:10.1093/carcin/bgi002 · Cited by 48
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases
Mazitschek, R., & Giannis, A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.009 · Cited by 45
Kim, J. S., Jeung, H. K., Cheong, J., Maeng, H. M., Lee, S., Hahn, J. S., Ko, Y. W., & Min, Y. H. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04759.x · Cited by 38
Natarajan, S., Chen, Z., Wancewicz, E. V., Monia, B. P., & Corey, D. R. (2004) · Oligonucleotides · doi:10.1089/oli.2004.14.263 · Cited by 37
Li, G., Sham, J. S. T., Yang, J., Su, C., Xue, H., Chua, D. T.-T., Lichen, S., Zhang, Q., Cui, Z., Wu, M., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20581 · Cited by 33
Wakabayashi, K., Saito, H., Ebinuma, H., Saito, Y., Takagi, T., Nakamura, M., Umezawa, A., Hata, J., & Ishii, H. (2000) · Oncology Reports · doi:10.3892/or.7.2.285 · Cited by 30
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Hepatocellular carcinoma: a global view
Yang, J. D., & Roberts, L. R. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.100 · Cited by 1,286
Self-citationYan, L.-X., Huang, X.-F., Shao, Q., Huang, M.-Y., Deng, L., Wu, Q.-L., Zeng, Y.-X., & Shao, J.-Y. (2008) · RNA · doi:10.1261/rna.1034808 · Cited by 1,148
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Metadata
- Authors
- Roberts, L. R., & Gores, G. J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005-05
- Volume
- 25
- Issue
- 02
- Pages
- 212-225
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2021760512
- Cited by
- 289
- References
- 75
- FWCI
- 12.24
- Type
- journal article
- Language
- de
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.